ATYR

3.8604.61%
TP

Timothy P. Coughlin

Independent Chairman of the Board

Mr. Timothy P. Coughlin, also known as Tim, CPA, has been the Director at Vir Biotechnology, Inc. since June 09, 2026. He had been an Independent Director at Fate Therapeutics, Inc. since August 2013 until May 30, 2025. Mr. Coughlin joined the Fate Therapeutics, Inc. in August 2013. Mr. Coughlin had been director at Peloton Therapeutics, Inc. since April 2019 until 2019. He served as Executive officer of Neurocrine Biosciences, Inc. since February 25, 2017 until 2018. Mr. Coughlin served as the Chief Financial Officer and Vice President of Neurocrine Biosciences, Inc. from September 2006 to February 25, 2017. He was responsible for Accounting, Finance, Information Technology and Investor Relations. Mr. Coughlin served as Controller of Neurocrine Biosciences, Inc. Prior to joining Neurocrine in 2002, he was with Catholic Health Initiatives (CHI), where he served as Vice President, Financial Services. Mr. Coughlin also served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors, from 1989 to 1999. He has been an Independent Director at Travere Therapeutics, Inc. (formerly known as Retrophin, Inc.) since March 31, 2015. He has been an Independent Director at aTyr Pharma, Inc. since April 10, 2017 and serves as Independent Chairman of Board since March 2024. He holds a B.A. in Accounting from Temple University and a Master's degree in International Business from San Diego State University. Mr. Coughlin is a Certified Public Accountant in both California and Pennsylvania. Mr. Timothy P. Coughlin is Director of ADC Therapeutics SA from June 3, 2025.

Positions